{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:10:04Z","timestamp":1790871004079,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-invasive tests (NITs) triage individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) for advanced fibrosis (AF). However, evidence for performance in metabolic dysfunction and alcohol-associated liver disease (MetALD) remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To determine how commonly used NITs perform in MetALD and MASLD using magnetic resonance elastography (MRE) as the reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults (\u2265\u200918 years) with MASLD \/MetALD with cardiometabolic risk factors (CMRFs) and MRI proton density fat fraction-defined steatosis were included. Fibrosis-4 (FIB-4), AST platelet ratio index (APRIF), and NAFLD fibrosis score (NFS) were estimated. Contemporaneous MRE served as the comparator with a cut-off for AF of 3.53\u00a0kPa and sensitivity analysis at 3.6\u00a0kPa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 1010 individuals [44 (35-54 years), 35.2% females], 842(83.3%) had MASLD and 168(16.6%) had MetALD. CMRF [diabetes,36.6% vs.30.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15], hypertension (38.2% vs. 34.5%\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.36), dyslipidaemia (31.5% vs. 33.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.55), and burden of AF (15.4% vs. 18.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.33) were similar. APRI was suboptimal [AUC 0.63 (0.60\u20130.66)]. In MASLD, the AUC for FIB-4 and NFS were 0.77 (0.72\u20130.82) and 0.80 (0.76\u20130.85), respectively. For MetALD, the AUC of FIB-4 and NFS were 0.78 (0.68\u20130.87) and 0.81 (0.70\u20130.89), respectively. FIB-4 (AUC 0.770 vs. 0.782,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.99) and NFS (AUC 0.804 vs. 0.80,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.94) had similar performance. Sensitivity analysis at 3.6\u00a0kPa threshold yielded similar results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a liver clinic cohort, MASLD and MetALD showed similar CMRF and AF burden. FIB-4 and NFS, but not APRI, show clinically useful and similar performance for AF, supporting inexpensive standard NIT-based triage in MetALD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04839-w","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:03:53Z","timestamp":1776510233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Blood-based non-invasive tests show comparable accuracy in MetALD and MASLD for MRE-defined advanced fibrosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Akash","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surabhi","family":"Jajodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shardhya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Keyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awanish","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Sonthalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourish","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday Chand","family":"Ghoshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh Kumar","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"2","key":"4839_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.17846","volume":"59","author":"R Loomba","year":"2024","unstructured":"Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(2):150\u20136.","journal-title":"Aliment Pharmacol Ther"},{"key":"4839_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"4839_CR3","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542.","journal-title":"J Hepatol"},{"key":"4839_CR4","doi-asserted-by":"publisher","first-page":"101271","DOI":"10.1016\/j.jhepr.2024.101271","volume":"7","author":"G Feng","year":"2025","unstructured":"Feng G, Targher G, Byrne CD, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7:101271.","journal-title":"JHEP Rep"},{"key":"4839_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31:S32\u201350.","journal-title":"Clin Mol Hepatol"},{"key":"4839_CR6","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.jceh.2024.102415","volume":"15","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas M, Othman HA, Elbadry M, et al. Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma. J Clin Experimental Hepatol. 2025;15:102415.","journal-title":"J Clin Experimental Hepatol"},{"key":"4839_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"4839_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD\u2010related events: A systematic review. Liver Int. 2021;41:261\u201370.","journal-title":"Liver Int"},{"key":"4839_CR9","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","volume":"81","author":"JH Oh","year":"2024","unstructured":"Oh JH, Ahn SB, Cho S, et al. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol. 2024;81:772\u201380.","journal-title":"J Hepatol"},{"key":"4839_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/hepr.14117","volume":"55","author":"Y Ogawa","year":"2025","unstructured":"Ogawa Y, Tomeno W, Imamura Y, et al. Distribution of Fibrosis-4 index and vibration\u2010controlled transient elastography\u2010derived liver stiffness measurement for patients with metabolic dysfunction\u2010associated steatotic liver disease in health check\u2010up. Hepatol Res. 2025;55:191\u20139.","journal-title":"Hepatol Res"},{"key":"4839_CR11","doi-asserted-by":"publisher","unstructured":"Munk Lauridsen M, Ravnskjaer K, Gluud LL et al. Disease classification, diagnostic challenges, and evolving clinical trial design in MASLD. J Clin Invest. 2025;135. https:\/\/doi.org\/10.1172\/JCI189953.","DOI":"10.1172\/JCI189953"},{"key":"4839_CR12","doi-asserted-by":"publisher","first-page":"111931","DOI":"10.1016\/j.ejrad.2025.111931","volume":"183","author":"H Gottfriedova","year":"2025","unstructured":"Gottfriedova H, Dezortova M, Sedivy P, et al. Comparison of ultrasound to MR and histological methods for liver fat quantification. Eur J Radiol. 2025;183:111931.","journal-title":"Eur J Radiol"},{"key":"4839_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"J-X Liang","year":"2023","unstructured":"Liang J-X, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79:592\u2013604.","journal-title":"J Hepatol"},{"key":"4839_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/apt.17564","volume":"58","author":"BK Kim","year":"2023","unstructured":"Kim BK, Bernstein N, Huang DQ, et al. Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD. Aliment Pharmacol Ther. 2023;58:229\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"4839_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.32163","volume":"75","author":"P Gin\u00e8s","year":"2022","unstructured":"Gin\u00e8s P, Castera L, Lammert F, et al. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022;75:219\u201328.","journal-title":"Hepatology"},{"key":"4839_CR16","doi-asserted-by":"publisher","unstructured":"Park H, Yoon EL, Kim M et al. Diagnostic performance of the fibrosis-4 index and the NAFLD fibrosis score for screening at-risk individuals in a health check-up setting. Hepatol Commun. 2023;7. https:\/\/doi.org\/10.1097\/HC9.0000000000000249.","DOI":"10.1097\/HC9.0000000000000249"},{"key":"4839_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","volume":"13","author":"A Duseja","year":"2023","unstructured":"Duseja A, Singh SP, De A, et al. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). J Clin Experimental Hepatol. 2023;13:273\u2013302.","journal-title":"J Clin Experimental Hepatol"},{"key":"4839_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71:1006\u201319.","journal-title":"Gut"},{"key":"4839_CR19","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021;161:1657\u201369.","journal-title":"Gastroenterology"},{"key":"4839_CR20","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/j.jhep.2024.05.027","volume":"81","author":"A De","year":"2024","unstructured":"De A, Mehta M, Duseja A. Substantial overlap between NAFLD and MASLD with comparable disease severity and non-invasive test performance: An analysis of the Indian Consortium on MASLD (ICOM-D) cohort. J Hepatol. 2024;81:e162\u20134.","journal-title":"J Hepatol"},{"key":"4839_CR21","doi-asserted-by":"publisher","unstructured":"D\u00edaz LA, Tavaglione F, Mittal N et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol Commun. 2025;9. https:\/\/doi.org\/10.1097\/HC9.0000000000000718","DOI":"10.1097\/HC9.0000000000000718"},{"key":"4839_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/apt.70281","volume":"62","author":"N Torp","year":"2025","unstructured":"Torp N, Israelsen M, Johansen S, et al. <scp\u2009>\u2009M\u2009et <scp\u2009>\u2009ALD: Diagnosis and Prognosis With Non-Invasive Tests<\/scp\u2009><\/scp\u2009>. Aliment Pharmacol Ther. 2025;62:990\u20131002.","journal-title":"Aliment Pharmacol Ther"},{"key":"4839_CR23","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera I, Thiele M, Serra-Burriel M, et al. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clin Gastroenterol Hepatol. 2022;20:2567\u2013e25766.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4839_CR24","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","volume":"70","author":"J Jung","year":"2021","unstructured":"Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021;70:1946\u201353.","journal-title":"Gut"},{"key":"4839_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/jcu.24010","volume":"53","author":"N Dag","year":"2025","unstructured":"Dag N, Sarici B, Igci G, et al. Diagnostic Performance of Ultrasound-Based Liver Fat Quantification With Reference to Magnetic Resonance Imaging Proton Density Fat Fraction and Histology. J Clin Ultrasound. 2025;53:1265\u201371.","journal-title":"J Clin Ultrasound"},{"key":"4839_CR26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/apt.18506","volume":"61","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione F, Amangurbanova M, Yang AH, et al. Head-to\u2010Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of <\u2009scp>MetALD Versus <\u2009scp>MASLD: A Prospective Study. Aliment Pharmacol Ther. 2025;61:1043\u201354.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04839-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:21:26Z","timestamp":1781648486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4839"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04839-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior ethical committee approval obtained from the Institutional Ethical Committee of Apollo Multiscpeciality Hospitals, vide number IEC\/BR\/2024\/03\/06, and the study adhered to the Declaration of Helsinki, with informed consent to participate being obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"329"}}